Top NYC, NY Biotech Companies (113)
The Genesis Biotechnology Group is a consortium of vertically integrated corporate entities, which facilitate the overall market implementation and delivery of basic science products such as diagnostic assays and drug discovery. Through the consolidation of research activities in the fields of biotechnology, molecular biology, genome research, biochemistry, nano and biophysics, bioinformatics, and computer science, we are able to cultivate research partnerships between highly productive research teams that break through the barriers of traditional disciplinary boundaries. Our mission is to improve the patient's quality of life through the cross-linking of basic science research and implementation in the clinical laboratory.
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. We use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic solutions that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer.
C16 Biosciences uses innovative processes found in nature to brew sustainable alternatives to palm oil. Palm oil is everywhere: it’s in our food, clothes, shampoo, and even the fuel that powers our cars. But this $61 billion industry has drastic environmental and societal costs: rainforests from Costa Rica to Indonesia are destroyed to make way for oil palm tree plantations, releasing carbon dioxide into the atmosphere and destroying habitats for people and endangered wildlife along the way. But palm oil doesn't have to be a problem. There remains an urgent need for consumers and companies alike to switch to environmentally conscious, sustainable palm oil products. C16 was founded with the objective of creating a sustainable, environmentally friendly alternative to conflict palm oil. By offering producers, refiners, traders and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability efforts, our aim is to reduce the environmental footprint of palm oil production and protect precious natural land, wildlife, and resources in the process. We've developed technology to brew a sustainable alternative to palm oil from microbes. Fermentation is a well-proven commercial process that has been used for centuries to convert raw materials into consumable commercial products consumed by billions of people every day. We believe that brewing palm oil like beer is the best and most likely path to developing a truly sustainable palm oil alternative. Our palm oil is sustainable -- it doesn't involve deforestation, endangering precious animal species, or forcing inhumane labor practices. The result is a world where consumers can enjoy the products they love without worrying about the dangerous practices involved in making them.
Melonfrost has created a novel way to modify living things. By combining machine learning and evolutionary biology, our Maia™ software can steer the evolution of organisms in real-time. Our platform, which includes our proprietary Evolution Reactor™, is the dawn of the next generation of biotechnology tools - allowing us to more efficiently solve problems in therapeutics, biomaterials, food, and energy.
For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.
Viome is on a mission to prevent and reverse chronic diseases. Viome is a high-growth biotech startup that applies AI and machine learning to biological data – e.g., microbiome, transcriptome and metabolome data – to provide direct-to-consumer personalized dietary and lifestyle recommendations for healthier living. We are a small, fast-growing, interdisciplinary team of passionate experts in biochemistry, microbiology, medicine, artificial intelligence, and machine learning with a shared mission to make illness optional.
Volastra Therapeutics, Inc. is a clinical stage oncology biotechnology company based in New York City. Founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento, Volastra is focused on developing therapeutics that exploit chromosomal instability (CIN) as a unique vulnerability in cancer. The company has grown since its founding in 2019 and now supports ongoing discovery efforts as well as a growing clinical organization. Volastra most advanced pipeline medicines are 2 distinct inhibitors of KIF18A, a novel therapeutic target. The first medicine, VLS-1488 was internally discovered and is currently in Phase I for the treatment of advanced cancers. The second KIF18A inhibitor is sovilnesib, a clinical stage KIF18A inhibitor licensed from Amgen in February 2023 and for which the company is in the process of initiating a Phase 1b trial in Q1 2024. Volastra is financed by top US and European venture firms, including Arch Ventures, Polaris Partners, Vida Venture, Droia Ventures, Catalio Capital as well as from strategic investor Eli Lilly. In addition to venture funding, Volastra has a multi-year drug discovery collaboration with Bristol Myers Squibb and a biomarker discovery partnership with Microsoft to use artificial intelligence to measure chromosomal instability. The company has a highly experienced senior leadership team and a world class advisory board. The company operates out of office and laboratory space in West Harlem, New York City, within easy traveling distance of most areas of the city, Westchester County, and New Jersey. Please visit www.volastratx.com for more information.
Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. For more information, please visit http://www.vant.ai.
.png)
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
Conceivable has developed the world’s first fully automated IVF lab. Our end-to-end reinvention of today’s largely manual, artisanal labs delivers new levels of precision, quality, and scalability. Simultaneously, Conceivable brings the innovation of modern cell therapies to IVF. We are already exceeding the clinical benchmarks of today’s best IVF labs. Worldwide 95% of the infertile population–and 80% in the United States–don’t have access to IVF. Conceivable exists to change this. By automating the IVF lab we will vastly broaden the availability of this Nobel Prize winning therapy, improve results, and meet the demands of millions of infertile people wishing to achieve the dream of becoming parents.
Astrix is the unrivaled market-leader in creating & delivering innovative strategies, solutions, and people to the life science community. Through world class people, process, and technology, Astrix works with clients to fundamentally improve business & scientific outcomes across many domains including the laboratory, clinical & regulatory, pharmacovigilance, R&D, and manufacturing. Founded by scientists to solve the unique challenges of the life science community, Astrix offers a growing array of strategic, application & platform, data transformation & analytics, change management, and staffing services designed to deliver immediate value to clients and solve their most complex technical and staffing challenges.
We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.
Our clinical trial solutions empower biopharma, medical device and CRO organizations to accelerate development. Contact us for trial management services.
Emergence's goal is to advance the science of agents and the creation of multi-agent systems for the Enterprise
Stern Investor Relations is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information, email info@sternir.com or visit our website at www.sternir.com
Output Biosciences is the world’s first preventative therapeutics company that extends human healthspan by combating chronic disease.
LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medical College and the University of California, San Diego, two preeminent institutions on the cutting edge of gene therapy research. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates in rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.
